Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities

Bibliography

• Exjade (deferasirox) tablets for oral suspension. Prescribing information. Novartis pharmaceutical corporation USA (NDA 21–882), 1 – 12 October 2006
   Google Scholar
• Nisbet-Brown E, Olivieri NF, Giardina PJ, Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003;361:1597-602
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. Effects of ICL670 (deferasirox) on cardiac iron concentrations. Lancet 2005;366:804
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Economides CH, Eracleous E, Kontoghiorghes GJ. Long term comparative studies inthalassemia patients treated with deferoxamine or deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. Hemoglobin 2008;32:41-7
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients. Hemoglobin 2009;33:332-8
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities. Expert Opin Drug Saf 2007;6:236-9
   Web of Science ®Google Scholar
• Kontoghiorghes GJ. Ethical issues and risk/benefit assessment on iron chelation therapy: advances with deferiprone/deferoxamine combination and concerns on deferasirox's safety, efficacy and costs. Hemoglobin 2008;32:1-15
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Porter JB, Cappellini MD, Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassaemia. Blood 2010;115:2364-71
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac iron and the prevention of heart disease in thalassemia. The protocol of the International Committee on Oral Chelators. Hemoglobin 2006;30:239-49
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Westwood MA, Holden S, Myocardial iron clearance with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004;127:348-55
   PubMed Web of Science ®Google Scholar
• Tanner MA, Galanello R, Dessi C, A randomised, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance. Circulation 2007;115:1876-84
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients. Expert Opin Drug Saf 2008;7:1-2
   PubMedGoogle Scholar
• Cappellini MD, Porter J, El-Beshlawy A, Tailoring iron chelation by iron intake and serum ferritin: prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010;95:557-66
   PubMed Web of Science ®Google Scholar
• Rafat C, Fakhouri F, Ribeil JA, Fanconi syndrome due to deferasirox. Am J Kidney Dis 2009;54:931-4
   PubMed Web of Science ®Google Scholar
• Papadopoulos N, Vasiliki A, Aloizos G, Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major. Ann Pharmacother 2010;44:219-21
   PubMed Web of Science ®Google Scholar
• Exjade (deferasirox) Prescribing Information Novartis. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm200850.htm. [1 – 15 January 2010]
   Google Scholar
• Hohneker JA. Exjade (deferasirox) tablets for oral suspension. Prescribing information. Novartis pharmaceutical corporation USA, 1 – 6 February 2010
   Google Scholar
• Kontoghiorghes GJ, Neocleous K, Kolnagou A. Benefits and risks of deferiprone in iron overload in thalassemia and other conditions. Comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf 2003;26(8):553-84
   PubMed Web of Science ®Google Scholar
• Sofroniadou K, Drossou M, Foundoulaki L, Acute bone marrow aplasia associated with intravenous administration of deferoxamine (desferrioxamine). Drug Saf 1990;5:152-4
   PubMed Web of Science ®Google Scholar
• Robins-Browne RM, Pipic JK. Desferrioxamine and systemic yersiniosis. Lancet 1983;2:1372
   PubMed Web of Science ®Google Scholar
• Boelaert JR, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis 1991;18:660-7
   PubMed Web of Science ®Google Scholar
• Polson RJ, Jawad AS, Bomford A, Treatment of rheumatoid arthritis with desferrioxamine. Q J Med 1986;61:1153-8
   PubMedGoogle Scholar
• Kontoghiorghes GJ, Kolnagou A, Peng CT, Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases. Expert Opin Drug Saf 2010;9:201-6
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Pattichi K, Hadjigavriel M, Kolnagou A. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). Transfus Sci 2000;23:211-23
   PubMedGoogle Scholar
• Beau-Salinas F, Guitteny MA, Donadieu J, High doses of deferiprone may be associated with cerebellar syndrome. BMJ 2009;338:a2319
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide. Hemoglobin 2008;32:608-15
   PubMed Web of Science ®Google Scholar
• Morales NP, Yamanont P, Jirasomprasert T, Bioequivalence study of a film-coated tablet of deferiprone in healthy Thai volunteers. Int J Clin Pharmacol Ther 2009;47:358-64
   PubMed Web of Science ®Google Scholar
• Zurlo MG, De Stefano P, Borgna-Pignatti C, Survival and causes of death in thalassaemia major. Lancet 1989;2:27-9
   PubMed Web of Science ®Google Scholar
• Tefler P, Goen PG, Christou S, Survival of medically treated thalassaemia patients in Cyprus. Trends and risk factors over the period 1980–2004. Haematologica 2006;91:1187-92
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Kontoghiorghes GJ. New golden era of chelation therapy in thalassaemia: the achievement and maintenance of normal range body iron stores. Br J Haematol 2010. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Farmaki K, Tzoumari I, Pappa C, Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 2010;148:466-75
   PubMed Web of Science ®Google Scholar
• Angelucci E, Barosi G, Camaschella C, Italian Society of hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica 2008;93:741-52
   PubMed Web of Science ®Google Scholar
• Wood JC, Kang BP, Thompson A, The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood 2010. [Epub ahead of print]
   Google Scholar
• Cohen AR, Galanello R, Piga A, Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003;102:1583-7
   PubMed Web of Science ®Google Scholar
• Maggio A, Vitrano A, Capra M, Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. Br J Haematol 2009;145:245-54
   PubMed Web of Science ®Google Scholar